Buscar
Kodiak Sciences Inc
KODAñadir a la lista de seguimiento
41.580USD
-0.920-2.16%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
2.60BCap. mercado
PérdidaP/E TTM
Más Datos de Kodiak Sciences Inc Compañía
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Información de Kodiak Sciences Inc
Símbolo de cotizaciónKOD
Nombre de la empresaKodiak Sciences Inc
Fecha de salida a bolsaOct 04, 2018
Director ejecutivoPerlroth (Victor)
Número de empleados109
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 04
Dirección1250 Page Mill Rd
CiudadPALO ALTO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94304
Teléfono16502810850
Sitio Webhttps://kodiak.com/
Símbolo de cotizaciónKOD
Fecha de salida a bolsaOct 04, 2018
Director ejecutivoPerlroth (Victor)
Ejecutivos de Kodiak Sciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
211.93K
--
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
Independent Director
Independent Director
--
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
211.93K
--
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Kodiak Sciences Inc?
Los cinco principales accionistas de Kodiak Sciences Inc son: Mr. John A. Borgeson
¿Cuántas instituciones poseen acciones de Kodiak Sciences Inc (KOD)?
A fecha de 2026Q1, 311 instituciones poseen acciones de Kodiak Sciences Inc, con un valor de mercado combinado de aproximadamente 60.04M, lo que representa el 96.04% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 7956993.00.